Predictive value of maximum tumor dissemination (Dmax) in lymphoma patients treated with CD19-specific CAR T-Cells
Patients with high Dmax showed a shorter PFS, but no significant differences in OS. Dmax is a useful parameter for characterizing tumor dissemination, which could also be incorporated into scores due to its interval scale.
Authors
- Christian Schmidt (ORCID: https://orcid.org/0009-0008-7402-2807)
- Veit Bücklein (ORCID: https://orcid.org/0000-0001-7391-7280)
- Michael Winkelmann (ORCID: https://orcid.org/0000-0003-4655-7341)
- Kai Rejeski (ORCID: https://orcid.org/0000-0003-3905-0251)
- Gabriel T. Sheikh (ORCID: https://orcid.org/0000-0002-7026-9203)
- Jens Ricke (ORCID: https://orcid.org/0000-0001-8762-8594)
- Viktoria Blumenberg (ORCID: https://orcid.org/0000-0003-1379-0876)
- Wolfgang G. Kunz (ORCID: https://orcid.org/0000-0002-5021-1952)
- Matthias Brendel (ORCID: https://orcid.org/0000-0002-6522-4895)
- Philipp Achhammer
Institutions
- Broad Institute (US)
- German Cancer Research Center (DE)
- German Center for Neurodegenerative Diseases (DE)
- LMU Klinikum (DE)
- Munich Cluster for Systems Neurology (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Cancer Imaging
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1186/s40644-025-00959-w
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- Gilead Sciences
- Celgene
- Incyte
- Astellas Pharma
- MorphoSys